CONTEXT: Attention-deficit/hyperactivity disorder (ADHD) is the most prevalent psychiatric disorder of childhood. There is considerable evidence that brain dopamine is involved in ADHD, but it is unclear whether dopamine activity is enhanced or depressed. OBJECTIVE: To test the hypotheses that striatal dopamine activity is depressed in ADHD and that this contributes to symptoms of inattention. DESIGN: Clinical (ADHD adult) and comparison (healthy control) subjects were scanned with positron emission tomography and raclopride labeled with carbon 11 (D2/D3 receptor radioligand sensitive to competition with endogenous dopamine) after placebo and after intravenous methylphenidate hydrochloride (stimulant that increases extracellular dopamine by blocking dopamine transporters). The difference in [11C]raclopride's specific binding between placebo and methylphenidate was used as marker of dopamine release. Symptoms were quantified using the Conners Adult ADHD Rating Scales. SETTING: Outpatient setting. PARTICIPANTS: Nineteen adults with ADHD who had never received medication and 24 healthy controls. RESULTS: With the placebo, D2/D3 receptor availability in left caudate was lower (P < .05) in subjects with ADHD than in controls. Methylphenidate induced smaller decrements in [11C]raclopride binding in left and right caudate (blunted DA increases) (P < .05) and higher scores on self-reports of "drug liking" in ADHD than in control subjects. The blunted response to methylphenidate in caudate was associated with symptoms of inattention (P < .05) and with higher self-reports of drug liking (P < .01). Exploratory analysis using statistical parametric mapping revealed that methylphenidate also decreased [11C]raclopride binding in hippocampus and amygdala and that these decrements were smaller in subjects with ADHD (P < .001). CONCLUSIONS: This study reveals depressed dopamine activity in caudate and preliminary evidence in limbic regions in adults with ADHD that was associated with inattention and with enhanced reinforcing responses to intravenous methylphenidate. This suggests that dopamine dysfunction is involved with symptoms of inattention but may also contribute to substance abuse comorbidity in ADHD.
CONTEXT: Attention-deficit/hyperactivity disorder (ADHD) is the most prevalent psychiatric disorder of childhood. There is considerable evidence that brain dopamine is involved in ADHD, but it is unclear whether dopamine activity is enhanced or depressed. OBJECTIVE: To test the hypotheses that striatal dopamine activity is depressed in ADHD and that this contributes to symptoms of inattention. DESIGN: Clinical (ADHD adult) and comparison (healthy control) subjects were scanned with positron emission tomography and raclopride labeled with carbon 11 (D2/D3 receptor radioligand sensitive to competition with endogenous dopamine) after placebo and after intravenous methylphenidate hydrochloride (stimulant that increases extracellular dopamine by blocking dopamine transporters). The difference in [11C]raclopride's specific binding between placebo and methylphenidate was used as marker of dopamine release. Symptoms were quantified using the Conners Adult ADHD Rating Scales. SETTING:Outpatient setting. PARTICIPANTS: Nineteen adults with ADHD who had never received medication and 24 healthy controls. RESULTS: With the placebo, D2/D3 receptor availability in left caudate was lower (P < .05) in subjects with ADHD than in controls. Methylphenidate induced smaller decrements in [11C]raclopride binding in left and right caudate (blunted DA increases) (P < .05) and higher scores on self-reports of "drug liking" in ADHD than in control subjects. The blunted response to methylphenidate in caudate was associated with symptoms of inattention (P < .05) and with higher self-reports of drug liking (P < .01). Exploratory analysis using statistical parametric mapping revealed that methylphenidate also decreased [11C]raclopride binding in hippocampus and amygdala and that these decrements were smaller in subjects with ADHD (P < .001). CONCLUSIONS: This study reveals depressed dopamine activity in caudate and preliminary evidence in limbic regions in adults with ADHD that was associated with inattention and with enhanced reinforcing responses to intravenous methylphenidate. This suggests that dopamine dysfunction is involved with symptoms of inattention but may also contribute to substance abuse comorbidity in ADHD.
Authors: Nora D Volkow; Gene-Jack Wang; Dardo Tomasi; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank W Telang; Joanna S Fowler; Jean Logan; Christopher T Wong; James M Swanson Journal: J Neurosci Date: 2012-01-18 Impact factor: 6.167
Authors: Yannis Paloyelis; Philip Asherson; Mitul A Mehta; Stephen V Faraone; Jonna Kuntsi Journal: Neuropsychopharmacology Date: 2010-08-25 Impact factor: 7.853
Authors: Erica Bowton; Christine Saunders; Kevin Erreger; Dhananjay Sakrikar; Heinrich J Matthies; Namita Sen; Tammy Jessen; Roger J Colbran; Marc G Caron; Jonathan A Javitch; Randy D Blakely; Aurelio Galli Journal: J Neurosci Date: 2010-04-28 Impact factor: 6.167
Authors: Peter Manza; Sien Hu; Jaime S Ide; Olivia M Farr; Sheng Zhang; Hoi-Chung Leung; Chiang-shan R Li Journal: J Psychopharmacol Date: 2016-01-11 Impact factor: 4.153
Authors: Robert L Findling; L Eugene Arnold; Laurence L Greenhill; Christopher J Kratochvil; James J McGough Journal: Prim Care Companion J Clin Psychiatry Date: 2008